The European Commission published Annex 21 of the EU GMP Guide on 16 February 2022, and it came into operation six months later, on 21 August 2022. Four years on, it governs how fast a Canadian cannabis batch leaves an EU importer's quarantine area.
EU-GMP Annex 21 sets the GMP rules for a manufacturing and importation authorisation (MIA) holder that brings medicinal products into the EU from a third country such as Canada. For a Canadian Licensed Producer, the practical effect is simple. The importer's Qualified Person (QP) can only certify your batch after physical importation and customs clearance, and only if your documentation, transport records and quality agreement answer everything Annex 21 asks.
What EU-GMP Annex 21 requires when cannabis enters the EU
Annex 21 defines importation narrowly. It means physically bringing a product into the EU/EEA. A purely financial or paper transaction doesn't count, and no batch can be QP-certified before it has crossed the border and cleared customs.
Two sites carry import responsibilities, and both must operate under an MIA:
- The site of physical importation, where the shipment first lands and is received.
- The site of QP certification, where a Qualified Person reviews the batch and certifies it for release.
These can be the same building or two companies in two member states. Either way, the imported product goes into quarantine after receipt and stays there, in a segregated area or a system with equivalent security, until the QP signs.
Testing on importation
Annex 21 also restates the rule from Article 51 of Directive 2001/83/EC: a product with a marketing authorisation that comes from a third country must be tested in the EU on importation. The exception is an arrangement such as a Mutual Recognition Agreement. That EU testing has to cover every test needed to show the product meets its specification. For cannabis flower, expect the importer to run its own release panel on every Canadian batch. Your COA and the importer's numbers then get compared line by line (see our breakdown of why EU retest results differ from a Canadian COA).
One exclusion matters for traders. Product that enters the EU only to be re-exported, without processing or release onto the EU market, falls outside Annex 21. Anything destined for an EU pharmacy shelf sits squarely inside it, so build your documentation around what the QP must review.
The Annex 21 supplier pack: what a Canadian LP must provide
Annex 21 is written for the EU importer, but almost every obligation it places on the QP traces back to evidence only the manufacturer can produce. We group those obligations into what we call the Annex 21 supplier pack: six deliverables a Canadian LP should have ready before the first EU shipment.
| Annex 21 clause | What the EU QP needs | What the Canadian LP supplies |
|---|---|---|
| 5.1 and 5.3 | Full batch documentation in a readable format | Batch record, COA, release summary, translated where needed |
| 5.1.3 | Dispatch site, route, temperature records, customs papers | Shipping file with logger data and packing list |
| 5.4 | Proof the manufacturer is qualified and audited | Audit access, site master file, GMP certificate scope |
| 5.2 | Record retention equal to EU rules | Written retention policy covering batch records |
| 5.5 | Reconciliation of split batch quantities | Batch split log tied to each shipment |
| 6.1 and 6.3 | Ongoing stability data and retained samples | Stability protocol, results, Annex 19 sample plan |
Batch documentation and format
The QP must have access to full batch documentation at the time of certification. Clause 5.3 adds that documents must be in a format the importer understands, and it may be necessary to supply them in more than one language. A French-language batch record from a Quebec facility is legitimate. Handing it to a German QP without an agreed English version is a delay you created.
Audits and the GMP certificate scope
Clause 5.4 requires documentary evidence that the QP's site has qualified the third-country manufacturer and monitors it through periodic on-site audits, done directly or by a third party. Clause 5.1.1 also flags certificate scope: if your EU-GMP certificate covers specific buildings or units, the QP must confirm the batch came from those units. Product from an uncertified room can't be certified, however good the COA looks.
Every item in this pack belongs in the quality agreement between the LP and the EU importer, because Annex 21 clause 2.6 requires written agreements under Chapter 7. If a deliverable isn't in the contract, assume nobody owns it.
Where Canadian cannabis shipments stall under Annex 21
Plenty of Annex 21 delays have nothing to do with failed tests. They come from paperwork the QP can't close. Four friction points come up again and again.
Split batches without reconciliation
LPs often divide one cultivation batch across two or three shipments to match an importer's cash flow or quota. Clause 5.5 requires documentation that reconciles those quantities at the QP site, and any gap is investigated under the certifying QP's responsibility. For example, a 40 kg batch shipped as 25 kg and 15 kg needs one record showing both legs, with the export permit numbers, so that the totals close.
Temperature data that stops at the airport
Clause 5.1.3 asks for shipping details including the transportation route and temperature monitoring records. Some export files show logger data from the vault to the freight forwarder, then nothing until the EU warehouse. The QP needs the whole route. Transport deviations up to batch certification also feed the importer's Product Quality Review, so a missing segment doesn't disappear after one batch.
COA results the importer can't match
Annex 21 tells the QP's site to compare import testing results with the third-country manufacturer's COA and to document and investigate any discrepancy or out-of-trend result. Potency drift, terpene loss or a moisture shift between your ISO/IEC 17025 lab and the EU lab turns into a formal, documented investigation.
Retention samples and stability left undefined
The certifying QP is responsible for reference and retention samples under Annex 19 and for an ongoing stability program. That program can run at the Canadian site as an outsourced activity, provided the QP has full access to the data. Decide in advance who holds which samples (our guide to Annex 19 retention samples covers the split). LPs that leave this open usually discover the gap during the importer's first inspection.
Here's our position: a Canadian LP shouldn't ship split batches to an EU importer until its reconciliation log and end-to-end temperature records are built. Selling the second leg is easy. Explaining a 300 g gap to a QP isn't.
How to build Annex 21 readiness into your export process
Annex 21 compliance is cheapest when it's designed into the export workflow rather than assembled after a QP query. This sequence works for a first EU partner.
- Map both importer sites. Confirm in writing which MIA holder physically imports and which site performs QP certification.
- Agree the documentation language and format before the first batch, including which records are translated.
- Match every shipment to an EU-GMP-certified unit and keep the certificate scope in the batch file.
- Build one batch file per shipment: batch record, COA, Health Canada export permit, packing list, customs declaration and complete logger data.
- Log every batch split with quantities and permit numbers so reconciliation closes on the importer's side.
- Set the retention sample and stability responsibilities in the quality agreement, then share stability results on a fixed schedule.
Step 4 is where most of the time is saved. When the QP opens one file that already answers clause 5.1.3, certification is a straight review with no follow-up questions (our article on EU QP batch release walks through what that review covers).
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act. Every batch ships with ISO/IEC 17025-tested COA data, full traceability and the documentation EU importers need to complete QP certification for the medical channel.
Annex 21 rewards suppliers who think like the QP. If you're qualifying a Canadian source for EU import, contact AlphaLeaf to review our batch documentation package. Bring your checklist. We'll bring the file.
Frequently Asked Questions
What is EU-GMP Annex 21?
EU-GMP Annex 21 is the part of the EU GMP Guide that sets GMP requirements for MIA holders importing medicinal products from outside the EU/EEA. It came into operation on 21 August 2022 and covers physical importation, QP certification, documentation, quarantine and supplier oversight.
Does Annex 21 apply to cannabis flower imported from Canada?
It applies when an EU importer brings cannabis into the EU as a medicinal product under a manufacturing and importation authorisation. Product that only transits the EU for re-export, without processing or release onto the EU market, is outside its scope.
Can a QP certify a Canadian cannabis batch before it arrives in the EU?
No. Annex 21 states that QP certification takes place only after physical importation and customs clearance into an EU/EEA state. Until then, the batch stays in quarantine at the importer's site.
Why does the EU importer retest a batch that already has a Canadian COA?
Under Article 51 of Directive 2001/83/EC, products from third countries are tested on importation unless an arrangement such as a Mutual Recognition Agreement applies. Annex 21 then requires the importer to compare its results with your COA and investigate any discrepancy.
What shipping records does Annex 21 require from an exporter?
The QP site must hold documents showing the dispatch site, the site of physical importation, the transport route, temperature monitoring records and customs papers such as the packing list or import declaration. A gap in the temperature record stalls certification. Close it early.
